Ratings SenzaGen AB

Equities

Market Closed - Nasdaq Stockholm Other stock markets 11:29:48 2024-04-26 am EDT			5-day change	1st Jan Change
6.38 ^SEK	+0.31%		+2.90%	-12.36%

Mar. 25	Senzagen Receives Follow-Up Order Worth SEK 0.8 Million from the Global Chemicals Leader	CI
Mar. 22	SenzaGen AB Reports Earnings Results for the Full Year Ended December 31, 2023	CI

From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
The company has insufficient levels of profitability.
The company appears highly valued given the size of its balance sheet.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
SENZAGEN AB	-12.36%	14.08M		-
EXACT SCIENCES CORPORATION	-20.45%	10.82B		A-
IOVANCE BIOTHERAPEUTICS, INC.	+43.17%	3.25B		D+
GUARDANT HEALTH, INC.	-35.86%	2.11B		C
BGI GENOMICS CO., LTD.	-17.21%	2.08B	-	B-
VERACYTE, INC.	-29.81%	1.48B		C+
MARAVAI LIFESCIENCES HOLDINGS, INC.	+17.56%	1.02B		B-
SEEGENE, INC.	-4.37%	733M		C+
CAREDX, INC	-37.00%	391M		C-
ADAPTIVE BIOTECHNOLOGIES CORPORATION	-46.94%	383M		C-

Investor Rating

Trading Rating

ESG Refinitiv

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality